[go: up one dir, main page]

CR8992A - Analogos de biaril piperazinilpiridina sustituida - Google Patents

Analogos de biaril piperazinilpiridina sustituida

Info

Publication number
CR8992A
CR8992A CR8992A CR8992A CR8992A CR 8992 A CR8992 A CR 8992A CR 8992 A CR8992 A CR 8992A CR 8992 A CR8992 A CR 8992A CR 8992 A CR8992 A CR 8992A
Authority
CR
Costa Rica
Prior art keywords
piperazinilpiridina
biaril
analogos
replaced
binders
Prior art date
Application number
CR8992A
Other languages
English (en)
Inventor
A Blum Charles
Brielmann Harry
L Chenard Bertrand
Zheng Xiaozhang
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of CR8992A publication Critical patent/CR8992A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proveen analogas de biaril piperazinil-piridina sustituidos, en donde las variables son como ya se ha descripto en la presente. Tales compuestos son ligantes que pueden utilizarse para modular la actividad de un receptor especifico in vivo o in vitro, y que son particularmente utiles en el tratamiento de cuadros asociados con la activacion patologica de los receptores en seres humanos, animales domesticos y ganado. Tambien se proporcionan las composiciones farmaceuticas y los metodos para usar dichos compuestos en el tratamiento de esos desordenes, asi como metodos para usar dichos ligantes para estudios de localizacion de receptores.
CR8992A 2004-08-13 2007-03-13 Analogos de biaril piperazinilpiridina sustituida CR8992A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60172104P 2004-08-13 2004-08-13
US64179605P 2005-01-05 2005-01-05

Publications (1)

Publication Number Publication Date
CR8992A true CR8992A (es) 2007-08-14

Family

ID=36000525

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8992A CR8992A (es) 2004-08-13 2007-03-13 Analogos de biaril piperazinilpiridina sustituida

Country Status (24)

Country Link
US (2) US7662830B2 (es)
EP (1) EP1786800B1 (es)
JP (1) JP4955554B2 (es)
KR (1) KR20070046924A (es)
CN (1) CN101014587B (es)
AR (1) AR050194A1 (es)
BR (1) BRPI0514319A (es)
CA (1) CA2577301C (es)
CR (1) CR8992A (es)
EC (1) ECSP077318A (es)
HN (1) HN2007006799A (es)
IL (1) IL181040A0 (es)
MA (1) MA28857B1 (es)
MX (1) MX2007001696A (es)
MY (1) MY145822A (es)
NI (1) NI200700040A (es)
NO (1) NO20071243L (es)
NZ (1) NZ553388A (es)
PE (1) PE20060620A1 (es)
RU (1) RU2413726C2 (es)
SG (1) SG157399A1 (es)
TW (1) TW200605889A (es)
WO (1) WO2006026135A2 (es)
ZA (1) ZA200701530B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176437A1 (en) 2001-08-31 2003-09-18 D.M. Watterson Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
EP1644358A2 (en) * 2003-07-16 2006-04-12 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
MY145822A (en) * 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
EP1812007B1 (en) 2004-11-02 2011-09-07 Northwestern University Pyridazine compounds and methods
WO2006050389A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds, compositions and methods
AU2005317176A1 (en) * 2004-12-13 2006-06-22 Neurogen Corporation Piperazinyl-pyridine analogues
WO2006078992A2 (en) * 2005-01-19 2006-07-27 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
WO2007127474A2 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2007127375A2 (en) * 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
US20080153845A1 (en) * 2006-10-27 2008-06-26 Redpoint Bio Corporation Trpv1 antagonists and uses thereof
TWI362930B (en) * 2007-04-27 2012-05-01 Purdue Pharma Lp Trpv1 antagonists and uses thereof
US8343966B2 (en) * 2008-01-11 2013-01-01 Novartis Ag Organic compounds
AU2012225382B2 (en) * 2011-03-09 2016-10-27 Celgene Avilomics Research, Inc. PI3 kinase inhibitors and uses thereof
ES2390326B1 (es) * 2011-04-05 2013-08-14 Universidad Miguel Hernández De Elche Antagonistas de trpv1 y sus usos.
GEP20166432B (en) 2011-09-27 2016-02-10 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
JP6129199B2 (ja) * 2011-12-02 2017-05-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピペリジン誘導体、その医薬組成物及び使用
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
WO2014141104A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EA027732B1 (ru) 2013-07-30 2017-08-31 Янссен Сайенсиз Айрлэнд Юси Замещенные аналоги пиридина-пиперазинила в качестве противовирусных соединений против rsv
CN115060832B (zh) * 2022-08-18 2022-11-29 上海奥科达生物医药科技有限公司 奥卡西平口服混悬液中奥卡西平及防腐剂含量检测方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4921148B1 (es) 1970-12-28 1974-05-30
US3775326A (en) 1972-04-17 1973-11-27 Addressograph Multigraph Pressure fixable electroscopic printing powder
FR2262512A1 (en) 1974-03-01 1975-09-26 Synthelabo 2,4,6-Tri-substd. -1,3,5-triazines - with analgesic and psychotropic activity
DE2643753A1 (de) 1976-09-29 1978-04-06 Thomae Gmbh Dr K Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine
FI70411C (fi) * 1980-12-29 1986-09-19 Pfizer Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat
DE3609596A1 (de) * 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
CA2090027A1 (en) 1990-08-31 1992-03-01 Shoichi Chokai Pyrimidine derivatives and drugs
AU703263B2 (en) 1994-08-08 1999-03-25 Nippon Shinyaku Co. Ltd. Triazine derivative and medicine
US5962453A (en) 1995-08-08 1999-10-05 Nippon Shinyaku Co. Ltd. Triazine derivative and medicine
JP2002514195A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
ATE274510T1 (de) 1998-06-19 2004-09-15 Chiron Corp Glycogen synthase kinase 3 inhibitoren
DE19836697A1 (de) 1998-08-13 2000-02-17 Hoechst Marion Roussel De Gmbh Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU768720B2 (en) 1999-04-01 2004-01-08 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
EP1136483A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Piperazinyl]pyrimidone derivatives
AU2001262150A1 (en) 2000-03-23 2001-10-03 Mitsubishi Pharma Corporation 2-(nitrogen-heterocyclic)pyrimidone derivatives
AU2001268718B2 (en) * 2000-06-29 2006-01-05 Abbott Laboratories Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
JP2004525071A (ja) 2000-07-20 2004-08-19 ニューロジェン コーポレイション カプサイシン受容体リガンド
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
EP1247809A3 (en) 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
WO2002098864A1 (en) 2001-06-01 2002-12-12 F. Hoffmann-La Roche Ag Pyrimidine, triazine and pyrazine derivatives as glutamate receptors
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
EP2316831B1 (en) 2002-11-21 2013-03-06 Novartis AG 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
CN1820001A (zh) 2003-07-10 2006-08-16 神经能质公司 经取代的杂环二芳基胺类似物
EP1644358A2 (en) 2003-07-16 2006-04-12 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
CN1826328A (zh) 2003-07-22 2006-08-30 神经能质公司 经取代的吡啶－2－基胺类似物
MY145822A (en) * 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
AU2005317176A1 (en) 2004-12-13 2006-06-22 Neurogen Corporation Piperazinyl-pyridine analogues
WO2006078992A2 (en) 2005-01-19 2006-07-27 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
US8258143B2 (en) * 2006-06-28 2012-09-04 Duquesne University Of The Holy Ghost Methods of using substituted pyrrolo[2,3-d]pyrimidines for targeting tumor cells and treating cancer

Also Published As

Publication number Publication date
MX2007001696A (es) 2007-04-23
US8334382B2 (en) 2012-12-18
JP4955554B2 (ja) 2012-06-20
AR050194A1 (es) 2006-10-04
WO2006026135A2 (en) 2006-03-09
NI200700040A (es) 2008-04-01
NO20071243L (no) 2007-04-27
KR20070046924A (ko) 2007-05-03
US7662830B2 (en) 2010-02-16
RU2007106042A (ru) 2008-09-20
SG157399A1 (en) 2009-12-29
IL181040A0 (en) 2007-07-04
CA2577301A1 (en) 2006-03-09
AU2005280366A1 (en) 2006-03-09
US20060122394A1 (en) 2006-06-08
ZA200701530B (en) 2008-11-26
WO2006026135A3 (en) 2006-06-15
HN2007006799A (es) 2010-11-03
ECSP077318A (es) 2007-04-26
EP1786800B1 (en) 2017-01-04
JP2008509932A (ja) 2008-04-03
CA2577301C (en) 2014-05-27
CN101014587B (zh) 2013-12-18
TW200605889A (en) 2006-02-16
BRPI0514319A (pt) 2008-06-10
MY145822A (en) 2012-04-30
NZ553388A (en) 2011-01-28
EP1786800A2 (en) 2007-05-23
RU2413726C2 (ru) 2011-03-10
EP1786800A4 (en) 2009-05-06
MA28857B1 (fr) 2007-09-03
PE20060620A1 (es) 2006-08-11
CN101014587A (zh) 2007-08-08
US20110003813A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
CR8992A (es) Analogos de biaril piperazinilpiridina sustituida
NI200900023A (es) Análogos de 2-fenoxi pirimidinona
CR8497A (es) Derivados de azepinoindol como agentes farmaceuticos
MY148461A (en) Heteroaryl amide analogues as p2x7 antagonists
MX2013006634A (es) Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1.
MXPA05006123A (es) Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina.
CO6270312A2 (es) Moduladores de gpr40 bifenilo-sustituidos
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CL2012001673A1 (es) Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras.
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
UY31760A (es) Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de leucotrieno a4 hidrolasa
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
BRPI0512274A (pt) derivados de piperazina aril-substituìdos
NI201100183A (es) Antagonistas de ccr3 de arilsulfonamida 2, 5 - disustituida
WO2006081388A3 (en) Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues
NI201100185A (es) Antagonistas de ccr3 de arilsulfonamida
TW200621251A (en) Substituted biaryl quinolin-4-ylamine analogues
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos
UY29478A1 (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
CO6280529A2 (es) DERIVADOS DE AMIDA AROMÁTICOS DE ÁCIDO PENTANOICO COMO MODULADORES DE γ - SECRETOSA
WO2006071538A3 (en) Substituted biaryl analogues
DOP2005000164A (es) Analogos de biaril piperazinil-piridina sustituidos
GT200600462A (es) Derivados de 6-heteroarilpiridoindolona, su preparacion y su aplicacion terapeutica
ECSP067096A (es) Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6

Legal Events

Date Code Title Description
FC Refusal